A carregar...

Gilteritinib: potent targeting of FLT3 mutations in AML

Since the discovery of FMS-like tyrosine kinase-3 (FLT3)–activating mutations as genetic drivers in acute myeloid leukemia (AML), investigators have tried to develop tyrosine kinase inhibitors that could effectively target FLT3 and alter the disease trajectory. Giltertinib (formerly known as ASP2215...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Levis, Mark, Perl, Alexander E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7094008/
https://ncbi.nlm.nih.gov/pubmed/32208491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000174
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!